Board Change • Jun 01
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 5 experienced directors. No highly experienced directors. Independent Director Richard Ding is the most experienced director on the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Annuncio • May 23
Moberg Pharma AB (Publ) Approves the Election of Board Members On May 21, 2026. Moberg Pharma AB (publ) held its Annual General Meeting. The Annual General Meeting resolved, in accordance with the proposal of the shareholder Noster Capital Master Fund Limited ("Noster Capital"), on election of Lars Johansson, Jack Bradley and Daniel Kaufman as board members, all for the period until the end of the next Annual General Meeting. Lars Johansson was elected, in accordance with the proposal of both the Nomination Committee and Noster Capital, as the new Chairman of the Board for the period until the end of the next Annual General Meeting. Lars Johansson, born 1966, has over 30 years of experience in pharmaceuticals and medtech. Lars Johansson has held leading roles within the J&J Group with increasing business area responsibility, including as CEO of the Nordic operations (Johnson & Johnson AB 2011-2019, and Janssen AB 2019-2021). Lars Johansson has also held board positions in Schain Research AB, ProstaLund AB, RLS AB, and Läkemedelsindustriföreningen (the Swedish Association of the Pharmaceutical Industry). Lars Johansson holds a master's degree in business administration from Växjö University. Lars Johansson is currently a board member of Ciencia Research and Carponovum AB. Lars Johansson holds no shares in the Company and is independent in relation to the Company, its management, and major shareholders.Jack Bradley, born 1991, has more than a decade of experience in the investment management business. He joined Noster Capital in 2014, and became a Partner and Head of Research in 2017 covering a broad geographical and market-cap investment universe, frequently giving input to company management teams on investor communication and investor relations strategy. He holds a degree in modern history from the University of Oxford. He is a resident of Norway and a British Citizen. Jack Bradley holds no shares in the Company, but Noster Capital (where he is a Partner) holds 3 055 423 shares in the Company. Jack Bradley is independent in relation to the Company, its management, and major shareholders.Daniel Kaufman, born 1968, has been a serial entrepreneur for the past 35 years, starting over a dozen companies, mostly in the technology sector. In the past 6 years, he shifted his focus to investing in public companies, with a focus on small cap value, and a recent large concentration in healthcare. Over these 6 years, his investment returns have exceeded 50% annually. He currently holds 5%+ positions in Harrow Inc. (HROW), Delcath Systems Inc. (DCTH) and Abeona Therapeutics (ABEO). Daniel Kaufman graduated from Williams College with a degree in political economy. Daniel Kaufman holds 1 409 456 shares in the Company and is independent in relation to the Company, its management, and major shareholders. Board Change • May 21
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 6 experienced directors. No highly experienced directors. Independent Director Nikolaj Sorensen is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Annuncio • Apr 18
Moberg Pharma AB (Publ) Announces Board Members Not Standing for Re-Elections Moberg Pharma AB (publ) announced that Jonas Ekblom, Otto Skolling and Nikolaj Sørensen have informed the nomination committee that they are not available for re-election at its Annual General Meeting to be held on May 21, 2026. Annuncio • Mar 13
Moberg Pharma AB Secures Additional Terbinafine Supplier For Mob-015 Moberg Pharma AB announced that an additional supplier of terbinafine has been approved for MOB-015 (drug for nail fungus). The regulatory approval process, initiated in April 2024, has now been positively completed. As a result, Moberg Pharma has thereby secured two alternative suppliers of terbinafine, each with the capacity to meet the company's global demand for terbinafine. This is in line with the company's overall quality efforts, ensuring a stable supply of the active ingredient. Annuncio • Oct 31
Moberg Pharma AB (publ), Annual General Meeting, May 21, 2026 Moberg Pharma AB (publ), Annual General Meeting, May 21, 2026. Annuncio • Sep 30
Moberg Pharma AB (publ) Approves Board Elections Moberg Pharma AB (publ) at its Extraordinary General Meeting held on September 29, 2025 approved the election of Fredrik Blom and Mona Zhang as new members of the Board of Directors for the period until the end of the next Annual General Meeting. Thus, the Board of Directors of the Company will, for the period until the next Annual General Meeting, consist of Jonas Ekblom (chairman of the board of directors), Nikolaj Sörensen, Isabelle Ducellier, Otto Skolling, Richard Ding, Fredrik Blom and Mona Zhang.Mona Zhang was born in 1981 and holds an MBA from Rotman and a bachelor's degree in electrical engineering from Beijing Institute of Technology. Mona Zhang has more than 15 years of experience in global investment management and corporate governance. Mona is the Founder and Managing Partner of Trunity Partners Ltd., a portfolio management firm registered with the Ontario Securities Commission in Canada, where she is responsible for capital allocation, operations, and compliance. Previously, she worked at Mackenzie Investments as a Portfolio Manager on the Global Equity and Income Team, focusing on investment research, portfolio construction, and risk oversight. Earlier in her career, she was with Burgundy Asset Management, specializing in international equity analysis. Today, Mona serves on the Boards of the Canadian Business History Association and the International Agama Zen Practice Centre. She is also a guest lecturer at the Rotman School of Management, University of Toronto. She is a CFA charterholder. Mona holds no shares in the Company as of the day of this notice and is independent in relation to the Company, its management and major shareholders.Fredrik Blom was born in 1970 and holds a master's degree in financial economics from Stockholm University. Throughout his professional career, Fredrik has primarily worked in sales, often within entrepreneurially driven companies. He has co-founded several companies, one of them is Svenska Studenthus, a real estate company focused on rental and student housing, which merged with K2A Fastigheter prior to the company's IPO on Nasdaq Stockholm in 2019. Fredrik has extensive experience in starting companies and developing their initial cash flows. Other companies Fredrik has co-founded and served on the board of include Jeff Fastigheter and RAW Properties. Fredrik holds 926,000 shares in the Company, directly and indirectly, as of the day of this notice. Fredrik is independent in relation to the Company, its management and major shareholders. Annuncio • Jun 25
Moberg Pharma AB (Publ) Announces Management Changes Moberg Pharma AB (publ) announced that in connection with the reorganization, Anders Bröijersén, Chief Medical Officer, and Robert Ehrl, Head of Supply, are leaving Moberg Pharma and the management team. Going forward, supply is incorporated into Christina Erixon's existing area of responsibility. The company's medical expertise is secured through consultants. Following these changes, Moberg Pharma's management team consists of Anna Ljung, Mark Beveridge, Annica Magnusson, and Christina Erixon. Annuncio • Dec 18
Moberg Pharma AB (Publ) Secures New Terbinafine Supplier Moberg Pharma AB (publ) announces that a new terbinafine supplier has been secured for MOB-015 (drug for nail fungus). As a result, terbinafine availability is no longer a limiting factor for the company's launch plans.
Over the past year, Moberg Pharma qualified a new terbinafine manufacturer with an authorized EU Certificate of Suitability (CEP) now available for MOB-015. Three product batches have been produced using terbinafine from the new supplier where available stability data confirm the shelf-life profile of MOB-015. The status is unchanged for the previously communicated approval process regarding the first additional terbinafine supplier, submitted in April. Moberg Pharma has earlier responded to all questions received from the Medical Products Agency and awaits the agency´s decision. As a result, Moberg Pharma expects to have several alternate terbinafine suppliers secured in the near future. Each of these suppliers has the capacity to meet the company's global terbinafine demand. Annuncio • Nov 08
Moberg Pharma AB (publ), Annual General Meeting, May 22, 2025 Moberg Pharma AB (publ), Annual General Meeting, May 22, 2025. Annuncio • Oct 11
Moberg Pharma AB (publ) to Report Fiscal Year 2024 Results on Feb 11, 2025 Moberg Pharma AB (publ) announced that they will report fiscal year 2024 results on Feb 11, 2025 Buy Or Sell Opportunity • Sep 13
Now 64% undervalued after recent price drop Over the last 90 days, the stock has fallen 55% to €1.00. The fair value is estimated to be €2.78, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 130% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 1,368% in 2 years. Earnings are forecast to grow by 100% in the next 2 years. Annuncio • Sep 13
Moberg Pharma AB (publ) Receives Information About Clinical Cure in a Subset of Patients in the Ongoing North American Phase 3 Study for MOB-015 Against Nail Fungus Moberg Pharma AB (publ) announced that the company has received information about clinical cure in a subset of patients in the ongoing North American Phase 3 study for MOB-015 against nail fungus. The number of patients who have achieved clinical cure in this blinded subset of patients is lower than the company's expectations, which necessitates that Moberg Pharma inform the market about this fact. The North American Phase 3 study is ongoing at 33 study centers in the US and Canada, including a total of 384 patients. The study constitutes an essential part of the clinical data required for the registration and commercialization of MOB-015 in the US and differs from previous studies with MOB-015, which is the basis for drug approval in 13 EU countries, by reducing the dosage - 8 weeks daily dosing followed by weekly maintenance treatment for 40 weeks, compared to daily dosing throughout the entire treatment period. In the process of preparing the database for upcoming topline data, the company has received information regarding clinical cure in a subset of patients in the study. Clinical cure is one of three parameters that together constitute the study's primary treatment goal, complete cure. All three parameters; clinical cure, negative fungal culture, and negative microscopy, need to be met for a patient to be considered completely cured. No information has been obtained about the other study parameters included in complete cure. The information obtained is blinded; no information has been received regarding which patient received active treatment or how many patients in the data subset received active treatment (patients in the study are randomized 2:1 to treatment with MOB-015 and vehicle). The total number of patients who have achieved clinical cure in this subset of patients is lower than the company's expectations, and Moberg Pharma assesses that the risk of not being able to commercialize the product in the US based on this study has significantly increased, which requires the company to inform the market of this fact. It is an absolute priority to protect the integrity of the study data, both as not to undermine the possibilities of using study results in discussions with regulatory authorities, and as there are patients with ongoing treatment in the study. Moberg Pharma will not speculate on possible outcomes or what this means for the future potential of MOB-015 and will await topline results to avoid drawing premature conclusions. Board Change • Jun 01
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 6 experienced directors. No highly experienced directors. Independent Director Nikolaj Sorensen is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. New Risk • May 28
New major risk - Revenue and earnings growth Earnings have declined by 57% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 57% per year over the past 5 years. Shareholders have been substantially diluted in the past year (185% increase in shares outstanding). Revenue is less than US$1m (kr820k revenue, or US$78k). Minor Risk Market cap is less than US$100m (€58.3m market cap, or US$63.4m). Buy Or Sell Opportunity • May 17
Now 21% undervalued Over the last 90 days, the stock has risen 50% to €2.18. The fair value is estimated to be €2.75, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 139% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 10,240% in 2 years. Earnings are forecast to grow by 92% in the next 2 years. Annuncio • May 16
Moberg Pharma AB (Publ) Elects Jonas Ekblom as Board Member Moberg Pharma AB (publ) at its Annual General Meeting held on May 14, 2024, approved the election of Jonas Ekblom as board member for a period until the end of the next Annual General Meeting. Annuncio • May 08
Moberg Pharma AB Announces MOB-015 Receives National Approvals for All Countries Included in the Decentralized Procedure Moberg Pharma AB announced that MOB-015 has received national approvals for all countries included in the decentralized procedure. MOB-015 is thus approved for the treatment of mild to moderate fungal infections of the nails in adults in 13 European countries. National approvals follow the completion of the decentralized procedure with a positive result where MOB-015 is recommended for approval in 13 European countries. The following EU countries are included: Austria, Belgium, Czech Republic, Denmark, Finland, France, Hungary, Ireland, Italy, Netherlands, Norway, Spain and Sweden. MOB-015 can be obtained with a prescription (Rx) in the Czech Republic, Denmark, Finland, France, Ireland and Spain, while it's approved as a non-prescription medicinal product, i.e. over-the-counter (OTC) in Austria, Belgium, Hungary, Italy, the Netherlands, Norway and Sweden. Annuncio • Nov 09
Moberg Pharma Announces Leadership Changes Moberg Pharma AB is strengthening its organization following market approval earlier this year and in preparation for the upcoming launch. The management team is welcoming two new members, Christina Erixon, Head of Pharmaceutical Development & Operations, who is replacing Agneta Larhed, and Robert Ehrl, Head of Supply, who is taking over from Jesper Lind. Both roles have been expanded from part-time consultants to full-time positions. Agneta Larhed is leaving the executive team but will remain a part-time consultant to the company with unchanged scope. Jesper Lind will also remain as a consultant to the company for a period. Christina Erixon has a broad experience of development, regulatory and quality within the pharmaceutical industry. Dr. Erixon has held leading positions within the pharmaceutical industry and at regulatory authorities, including roles as the manager of clinical trials at the Swedish Medical Products Agency, senior product developer at AstraZeneca, business manager and associate director for Pharmaceutical Development at APL, and most recently as the director of Drug Development at SDS Life Science. Dr. Erixon is a pharmacist with a doctoral degree in pharmaceutics from Uppsala University. Robert Ehrl holds a Ph.D. in organic chemist with over 20 years of experience in the pharmaceutical industry. He has held leadership positions at AstraZeneca and Valneva Sweden AB, primarily in process development, supply, and manufacturing. Dr. Ehrl has worked with both small molecule and biological drugs/vaccines, from active pharmaceutical ingredient (API) to final packed product. Annuncio • Oct 19
Moberg Pharma AB (publ) Appoints Nomination Committee Moberg Pharma AB (publ) appointed nomination committee. It comprises of Gillis Cullin, appointed by Östersjöstiftelsen, Ida Marie Lindberg, appointed by Kjelsmark Holding, Kerstin Valinder Strinnholm, Chairman of the Board. Annuncio • Oct 06
Moberg Pharma Completes Enrollment to the Phase 3 Study for Mob-015 in North America Moberg Pharma AB has completed the recruitment of 384 patients with onychomycosis (nail fungus) for the ongoing MOB-015 phase 3 study in North America. The aim is to provide a pivotal part of the clinical data set for registration and commercialization of MOB-015 in the U.S. Topline results are expected in January 2025. The enrollment to the North American study has now been completed with 384 patients randomized at 33 sites in the U.S. and Canada. Topline results are expected in January 2025. The patients are evaluated over 52 weeks and the primary endpoint is the proportion of subjects achieving complete cure of their target nail. The study design builds on the experience gained from the previous Phase 3 studies. Moberg Pharma cooperate with the same CRO, lead investigator and successful sites from the previous North American study. The purpose of the study is to facilitate market approval in the US as well as strengthen the product's clinical evidence and marketing claims globally. New Risk • Sep 03
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 178% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (46% average weekly change). Earnings are forecast to decline by an average of 43% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (178% increase in shares outstanding). Revenue is less than US$1m (kr207k revenue, or US$19k). Minor Risk Market cap is less than US$100m (€16.3m market cap, or US$17.5m). Annuncio • Aug 05
Moberg Pharma AB (publ) Announces National Approval for MOB-015 in Sweden Moberg Pharma AB announced that MOB-015 has received national approval for the company's home market, Sweden, for the treatment of mild to moderate fungal infections of the nails in adults. This is the second country to grant national approval for MOB-015, following the approval in Ireland announced July 31st, and Sweden is the first country where MOB-015 has been approved for over-the-counter (OTC) use. Grant of market authorization in Sweden is significant as commercialization rollout is planned to start in home market. The company will initiate the launch as quickly as possible and expect to initiate launch preparations in Sweden before the end of the year. National approvals follow the completion of the decentralized procedure with a positive outcome, where MOB-015 was recommended for national approval in 13 European countries. The following countries are included: Austria, Belgium, Czech Republic, Denmark, Finland, France, Hungary, Ireland, Italy, Netherlands, Norway, Spain and Sweden. Currently, national implementation in each country and granting of marketing authorizations including OTC-approvals when applicable, is ongoing. National approvals are expected to occur in the coming months and timelines may vary between countries. Annuncio • Aug 02
Moberg Pharma AB Announces That Mob-015 Has Receives National Approval in Ireland for the Treatment of Mild to Moderate Fungal Infections of the Nails in Adults Moberg Pharma AB announces that MOB-015 has received national approval in Ireland for the treatment of mild to moderate fungal infections of the nails in adults. Ireland is the first country to grant market authorization for Moberg Pharma's new onychomycosis treatment after the Decentralized Procedure concluded with a positive outcome, where MOB-015 was recommended for national approval in 13 European countries, see press release from June 28th 2023. The Decentralized Procedure includes the following EU countries: Austria, Belgium, Czech Republic, Denmark, Finland, France, Hungary, Ireland, Italy, Netherlands, Norway, Spain and Sweden. Currently, national implementation in each country and granting of marketing authorizations including OTC-approvals when applicable, is ongoing. National approvals are expected to follow during upcoming months and timelines may vary between countries. Annuncio • Jul 06
Moberg Pharma AB (publ) Announces Approval for Mob-015 in the European Union Cipher Pharmaceuticals Inc. announced that the Company's partner, Moberg Pharma AB, has obtained European Union approval for MOB-015 (nail fungus treatment) as a result of demonstrating superior levels of mycological cure (76% vs. 42% for comparators) and a significantly better complete cure rate. MOB-015 has been recommended for national approval in 13 European countries, which will be commercialized through partners such as Bayer and Allderma, and is expected to be launched in Nordic countries such as Sweden during 2023. Cipher holds the exclusive Canadian rights to MOB-015, a new topical treatment of Onychomycosis (nail fungus) based on Moberg's patented proprietary formulation of terbinafine. In Canada, according to IQVIA, the total prescription market for Onychomycosis was greater than $82 million at December 31, 2022 with a single product having over 90% market share. Moberg Pharma continues to invest and advance MOB-015 through an additional phase 3 trial of a total of 350 patients with sites across the United States and Canada. The purpose of this study is to facilitate market approval in North America as well as further strengthen the product's clinical evidence beyond the mycological and complete cure rates already demonstrated to the European Union. Patient enrollment in the clinical trial is progressing according to plan with full enrollment expected in 2023. New Risk • Jun 30
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 35% per year over the past 5 years. Revenue is less than US$1m (kr207k revenue, or US$19k). Market cap is less than US$10m (€7.87m market cap, or US$8.59m). Annuncio • Jun 29
Moberg Pharma AB (Publ) Recommends for Approval in EU Moberg Pharma AB announced that the Decentralized Procedure hasended with a positive outcome and that MOB-015 is recommended for national approval in 13 European countries for the treatment of mild to moderate fungal infections of the nails in adults. The approval in the European Union represents the first marketing authorizations for MOB-015's new onychomycosis treatment worldwide. Approval is supported by two Phase 3 trials where MOB-015 demonstrated superior levels of mycological cure (76% vs up to 42% for comparators), and a significantly better complete cure rate compared to vehicle, without any serious adverse reactions. MOB-015 is a topical formulation of terbinafine, enabling effective concentrations of terbinafine to the nail and nail bed while avoiding the risk of systemic exposure seen with oral terbinafine use. The Decentralized Procedure includes the following EU countries: Austria, Belgium, Czech Republic, Denmark, Finland, France, Hungary, Ireland, Italy, Netherlands, Norway, Spain and Sweden. Next steps include national implementation in each country and granting of marketing authorizations including OTC-approvals when applicable. National approvals are expected to follow during upcoming months and timelines may vary between countries. Board Change • Jun 01
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 5 experienced directors. 1 highly experienced director. Director Mattias Klintemar is the most experienced director on the board, commencing their role in 2015. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Annuncio • May 17
Moberg Pharma AB (Publ) Elects Håkan Wallin to the Board Members Moberg Pharma AB (publ) announced at annual general meeting held on May 16, 2023, the shareholders elected Håkan Wallin as board members for a period until the end of the next Annual General Meeting. Board Change • Jan 15
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Director Mattias Klintemar was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Annuncio • Nov 09
Moberg Pharma AB (publ) Appoints Anders Bröijersén as Chief Medical Officer and a Member of the Management Team Moberg Pharma AB (publ) appointed Anders Bröijersén as Chief Medical Officer and a member of the management team. Annuncio • May 18
Moberg Pharma AB (publ) Approves Board Appointments Moberg Pharma AB (publ) at its AGM held on May 16, 2022 approved the election of Kerstin Valinder Strinnholm and Anders Lundmark as directors for a period until the end of the next Annual General Meeting and resolved to elect Kerstin Valinder Strinnholm as Chairman of the Board. Annuncio • May 12
Peter Wolpert and Fredrik Granström Step-Down from the Board The nomination committee of Moberg Pharma AB (publ) announced that Current Chairman and founder Peter Wolpert is leaving the Board but will remain one of the company's major owners. Fredrik Granström is also stepping down from the Board but will retain his role as the company's legal advisor. Annuncio • May 10
Moberg Pharma AB (Publ) Begins Patient Enrollment in North American Phase 3 Study Moberg Pharma AB announced that patient enrollment has started in the North American Phase 3 study for MOB-015 (nail fungus treatment). Tbhe randomized, multicenter, vehicle-controlled Phase 3 study will include approximately 350 patients in North America. The patients will be evaluated over 52 weeks and the primary endpoint will be the proportion of subjects achieving complete cure of their target nail. The study design builds on the experience gained from the previous Phase 3 studies. Moberg Pharma will cooperate with the same CRO, lead investigator and successful sites from the previous North American study. The purpose of the new study is to facilitate market approval in the US as well as strengthen the product's clinical evidence and marketing claims globally. Annuncio • Feb 01
Moberg Pharma AB Announces Peter Wolpert and Fredrik Granström are Not Available for Re-Election Moberg Pharma AB announced that Peter Wolpert and Fredrik Granström, are not available for re-election for the Annual General Meeting of shareholders 2022. Annuncio • Dec 23
The Medical Products Agency in Sweden Will Be Reference Member State for Moberg Pharma's European Registration Application The Medical Products Agency in Sweden has agreed to be reference member state for Moberg Pharma AB's registration application for MOB-015 (nail fungus treatment). The company will submit the registration application in Europe through the decentralized process, and market approval is expected in 2023. Moberg Pharma will submit a full application, which offers the possibility of data exclusivity in Europe for up to 10 years following market approval. Moberg Pharma has been ready to submit the registration application as soon as the authority can receive it. Due to limited resources and many parallel ongoing applications, the Swedish Medical Products Agency has now announced that the application can be submitted in March 2022. The company's goal remains unchanged, to receive its first market approval and launch MOB-015 in 2023. Annuncio • Jun 11
Moberg Pharma AB Announces the Results from the North American Phase 3-Study with MOB-015 (topical terbinafine) for the Treatment of Onychomycosis Moberg Pharma AB announced that the results from the North American phase 3-study with MOB-015 (topical terbinafine) for the treatment of onychomycosis have been published in the Journal of the American Academy of Dermatology. In December 2019, Moberg Pharma announced positive top-line results from a phase 3-study including 365 patients, where the primary efficacy endpoint and the two key secondary efficacy endpoints were met. Mycological cure was achieved in 70% of patients receiving MOB-015 and complete cure was achieved in 4.5% of patients receiving MOB-015. Treatment success (mycological cure and almost or completely clear great toenail) assessed by the investigator was achieved in 15.4% of the patients. In the patients’ self-assessments, a clear majority (83%) of the patients completing the study reported improvement from MOB-015 as early as 12 weeks after starting treatment, and at week 52, 33% reported their treated toenails were cured or almost cured. Both physicians and patients assessment were consistent in showing that the high mycological cure rate achieved with treatment with MOB-015 translated into clinical benefit. The results are now published in the Journal of the American Academy of Dermatology, Volume 85, Issue 1, July 2021, Pages 95-104 and are available online. Annuncio • Jan 16
Moberg Pharma AB's Paid Subscription Units to Be Delisted The paid subscription units in Moberg Pharma AB will be delisted. Last trading day for MOB BTU will be on January 18, 2021. Is New 90 Day High Low • Dec 04
New 90-day low: €0.66 The company is down 50% from its price of €1.33 on 04 September 2020. The German market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 3.0% over the same period. Is New 90 Day High Low • Nov 11
New 90-day low: €0.88 The company is down 40% from its price of €1.46 on 12 August 2020. The German market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period. Annuncio • Nov 07
Moberg Pharma AB (publ) to Report Fiscal Year 2020 Results on Feb 09, 2021 Moberg Pharma AB (publ) announced that they will report fiscal year 2020 results at 7:14 AM, GMT Standard Time on Feb 09, 2021 Annuncio • Nov 06
Moberg Pharma AB (Publ) Appoints Nomination Committee Moberg Pharma AB (publ) announced that Nomination Committee ahead of the Annual General Meeting for the fiscal year July 2019 - December 2020 comprises: Peter Wolpert, Chairman of the Board; Gillis Cullin, appointed by Östersjöstiftelsen; Anders Lundmark; and Konrad Ziobro, appointed by Synskadades Stiftelse. Annuncio • Nov 05
Moberg Pharma AB (publ), Annual General Meeting, May 18, 2021 Moberg Pharma AB (publ), Annual General Meeting, May 18, 2021. Is New 90 Day High Low • Oct 16
New 90-day low: €1.15 The company is down 18% from its price of €1.40 on 17 July 2020. The German market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 12% over the same period. Is New 90 Day High Low • Sep 26
New 90-day low: €1.29 The company is down 14% from its price of €1.51 on 26 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period. Annuncio • Sep 21
Moberg Pharma AB (publ)(OM:MOB) dropped from S&P Global BMI Index Moberg Pharma AB (publ)(OM:MOB) dropped from S&P Global BMI Index